[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350006-105":59,"doc-detail-350006-en":122},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":115,"head_meta":117,"extra_data":119,"updated_unix":121},105,"en","deciphering-the-role-of-ki67-prognostic-insights-in-advanced-breast-cancer-therapy-with-cyclin-dependent-kinase-46-inhibitors","Deciphering the role of Ki67: prognostic insights in advanced breast cancer therapy with Cyclin-dependent kinase 4/6 inhibitors","","Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are established standard therapy for advanced breast cancer, yet Ki67’s prognostic relevance in metastatic disease remains uncertain. A retrospective analysis evaluated Ki67 in patients treated with CDK4/6i between 2018 and 2023, totaling 368 with available Ki67 results. Ki67 measured from different biopsy contexts showed continuous association with progression-free survival and overall survival, with higher expression linked to worse outcomes. Patients with low Ki67 demonstrated more favorable PFS and OS.",{"@graph":69,"@context":114},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/deciphering-the-role-of-ki67-prognostic-insights-in-advanced-breast-cancer-therapy-with-cyclin-dependent-kinase-46-inhibitors/350006/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/deciphering-the-role-of-ki67-prognostic-insights-in-advanced-breast-cancer-therapy-with-cyclin-dependent-kinase-46-inhibitors/350006.png","ImageObject",300,407,{"name":92,"@type":93},"\tJames","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108],{"name":109,"@type":110,"acceptedAnswer":111},"What outcomes were associated with Ki67 levels in this cohort?","Question",{"text":112,"@type":113},"Ki67 correlated with both progression-free survival (PFS) and overall survival (OS), with each unit increase in Ki67 linked to reductions in PFS and OS; low Ki67 showed longer median PFS and OS than high Ki67.","Answer","https://schema.org",{"og:url":83,"og:type":116,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":118,"canonical":83},"index,follow",{"doc_id":120,"site_id":62},350006,1790514720,{"code":4,"msg":5,"data":123},{"doc_id":120,"user_id":124,"nickname":92,"user_avatar":125,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":131,"language":132,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":133,"faqs":134,"seo_title":135,"seo_description":67,"update_tm":136,"read_time":137,"preview_page_count":19,"preview_urls":138},2336474466412,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Kubeczko etal. BMC Cancer (2026) 26:377 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-15594-2](https://doi.org/10.1186/s12885-026-15594-2)  \nRESEARCH Open Access  \nDeciphering the role of Ki67: prognostic insights in advanced breast cancer therapy with Cyclin-dependent kinase 4/6 inhibitors  \nMarcin Kubeczko 1*, Anna Polakiewicz-Gilowska 1, Katarzyna Świderska1, Marta Mianowska-Malec1,  \nAleksandra Leśniak1, Barbarba Łanoszka1, Konstanty Chomik1, Barbara Grandys1, Natalya Lisovska 1,  \nGrzegorz Woźniak2, Tomasz Latusek2, Ewa Stobiecka3, Jakub Simek3, Bartłomiej Pyciński4, Barbara Bobek-Billewicz5, Ewa Chmielik3 and Michał Jarząb1  \nAbstract  \nBackground Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are the standard of care in advanced breast cancer. While Ki67 is prognostic in early-stage disease, including adjuvant CDK4/6i, its role in metastatic setting is unclear. This study assessed Ki67’s prognostic value in advanced breast cancer treated with CDK4/6i.  \nMethods We conducted a retrospective analysis of patients with advanced breast cancer receiving CDK4/6i at our cancer center between 2018 and 2023.  \nResults The study included 368 patients with Ki67 results. The median age was 63 years (IQR 52–70 . 5) . 283 patients (76 . 9%) received CDK4/6i in the first-line. With respect to biopsy timing, Ki67 expression was evaluated in tissue samples from 319 patients in the metastatic setting and 49 patients in the early breast cancer setting. In terms of biopsy site, Ki67 was measured from the breast tumor in 235 patients, from regional lymph nodes in 26 patients, and from various metastatic sites in 107 patients. Ki67, as a continuous variable, correlated with PFS and OS. Specifically, each unit increase in Ki67 was associated with a 1% reduction in PFS and OS. Median PFS in patients with lowKi67 was 33.0 months vs. 22.0 months for highKi67 (p = 0 . 008) . Two-year PFS was 68 . 3% for lowKi67, vs. 48.4% for highKi67 . Median OS was 49.7 months for lowKi67 vs. 39.8 months for highKi67 (p = 0 . 027) .  \nConclusions Ki67 appears to be a prognostic factor in advanced breast cancer patients treated with CDK4/6i. Patients with low Ki67 had favorable prognosis.  \nKeywords Advanced breast cancer, Ki67, Ribociclib, Abemaciclib, Palbociclib  \n*Correspondence:  \nMarcin Kubeczko  \n[marcin.kubeczko@gliwice.nio.gov.pl](marcin.kubeczko@gliwice.nio.gov.pl)  \n1Breast Cancer Center, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, 15 Wybrzeze Armii Krajowej Street, Upper Silesia, 44-102 Gliwice, Poland  \n2Radiotherapy Department, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice 44-102, Poland  \n3Tumor Pathology Department, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice 44-102, Poland  \n4Faculty of Biomedical Engineering, Silesian University of Technology, Zabrze 41-800, Poland  \n5Radiology and Diagnostic Imaging Department, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice 44-102, Poland  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/.)[.](http://creativecommons.org/licenses/by/4.0/.)  \nK","cbCaiakdsv3rcC9e","https://ap.wps.com/l/cbCaiakdsv3rcC9e","pdf",1989797,11,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What outcomes were associated with Ki67 levels in this cohort?\",\"answer\":\"Ki67 correlated with both progression-free survival (PFS) and overall survival (OS), with each unit increase in Ki67 linked to reductions in PFS and OS; low Ki67 showed longer median PFS and OS than high Ki67.\"}]","Deciphering the role of Ki67: prognostic insights in advanced breast cancer therapy with Cyclin-dependent kinase 4/6 inhibitors | PDF",1790086690,28,[139,143,147,151],{"page_no":8,"url":140,"width":141,"height":142},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/085a02e90c5c5b53bea67b489f6c8f32.webp",983,1310,{"page_no":14,"url":144,"width":145,"height":146},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5d89f6fb4cdd2687bb08e23faf9f16b6.webp",982,1309,{"page_no":81,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7aee166e89688ad47696bc951780a3e3.webp",981,1308,{"page_no":19,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/329a85b7617b8e01208892bb738eaf54.webp",980,1306]